Sign in

CIK 0001737953 · Non-accelerated filer<br>Smaller reporting company

Replimune Group, Inc.

Sign in to watch
Ticker
REPL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Mar 31
Incorporated
DE
Entity type
operating
EIN
822082553
Phone
(781) 222-9600
Business address
500 UNICORN PARK, WOBURN, MA, 01801
  1. 4 Grant or award Chief Medical Officer acquired 50,000 shares (grant or award)
  2. 4 Derivatives Options or other derivatives
  3. 4 Grant or award Chief Accounting Officer acquired 36,667 shares (grant or award)
  4. 4 Grant or award Chief Executive Officer acquired 251,240 shares (grant or award)
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Grant or award Chief Financial Officer acquired 50,000 shares (grant or award)
  10. 4 Derivatives Options or other derivatives
  11. 4 Planned sale Chief Commercial Officer sold 6,500 shares at $8.01 ($52,065)
  12. 4 Gift Director gave 25,000 shares (gift)
  13. 4 Grant or award Chief Executive Officer acquired 200,000 shares (grant or award)
  14. 4 Grant or award Chief Medical Officer acquired 60,000 shares (grant or award)
  15. 4 Grant or award Chief Financial Officer acquired 60,000 shares (grant or award)
  16. 4 Grant or award Chief Commercial Officer acquired 35,000 shares (grant or award)
  17. 4 Grant or award Chief Accounting Officer acquired 10,000 shares (grant or award)
  18. 4 Open-market sale Director sold 3,169 shares at $10.40 ($32,958)
  19. 4 Planned sale Chief Executive Officer sold 10,000 shares at $11.13 ($111,300)
  20. 4 Open-market sale Chief Commercial Officer sold 5,208 shares at $9.10 ($47,393)

Page 2 of 16 · 316 filings